UPMC Physician Resources’ Post

🚨 A revolutionary fluorescent light system has just been approved for use in breast cancer surgeries. This innovative technology illuminates any remaining cancerous tissue in real-time, aiming to drastically reduce the need for follow-up surgeries. Statistics reveal that currently, one-third of patients undergo a second surgery, of which two-thirds do not show any residual cancer. This new system promises to enhance surgical precision and patient outcomes dramatically. #HealthTech #CancerCare #Innovation

🔍 Revisiting a Pivotal Study in Rectal Cancer Treatment 🔍 Meta-analysis "Comparison of Survival Among Adults With Rectal Cancer Who Have Undergone Laparoscopic vs Open Surgery" remains a cornerstone in our understanding of cancer surgery outcomes. Authored by Meng Kong, Hongyuan Chen, Keshu Shan, Hongguang Sheng, and Leping Li, this study provides invaluable insights into the long-term benefits of laparoscopic surgery for rectal cancer patients. 📈 Highlight: The study found a significantly better overall survival rate for laparoscopic surgery compared to open surgery, challenging previous concerns and advocating for its routine use. 🎓 Earn 1.0 CME Credit: This analysis not only advances our knowledge but also offers CME credits for healthcare professionals seeking to deepen their expertise. 💡 Let's reflect on how these findings continue to influence surgical choices and patient care strategies in oncology. https://lnkd.in/dXcN_CUU #MedicalEducation #CME #Oncology #RectalCancer #LaparoscopicSurgery #HealthcareProfessionals

Glowing dye that clings to cancer cells offers advancement in surgery, providing doctors with a 'second pair of eyes.' University of Oxford experts highlight that this innovation enables a more precise removal of cancer during operations. By reducing the chance of cancer recurrence, this technique also minimizes side effects such as incontinence and erectile dysfunction. #CancerResearch #MedicalInnovation

A recent study demonstrated the combination of ultrasound and immune-inflammatory markers predicted axillary lymph node metastasis (ALNM) in breast cancer patients with high accuracy. This is another example of ultrasound providing a non-invasive diagnostic method in contrast to invasive biopsies and surgery. How have you seen ultrasound benefit patients through non-invasive diagnoses? ➡️ Read the article here: https://hubs.ly/Q02DD-Vb0 #ultrasound #inflammatorymarkers #breastcancer #diagnostics

We are excited to announce that Optiscan Imaging Ltd has received ethical clearance from the Royal Melbourne Hospital Human Research Ethics Committee to commence an in vivo clinical study focused on breast cancer. This study will showcase the capabilities of our recently unveiled InVue™ precision surgery imaging platform. The InVue™ device will be used during surgeries to collect real-time imaging data of the surgical cavity after tumor removal, aiming to determine the clearance of the tumor on the spot. Optiscan CEO and Managing Director, Dr. Camile Farah, stated: “This non-interventional study design allows us to gather valuable imaging data without interfering with standard care. We anticipate progressing to an interventional protocol, where collected images will guide surgeons in real-time decision-making for optimal patient outcomes.” Stay tuned for more updates as we continue to advance precision surgery and improve patient care. https://lnkd.in/gQz2e2HW #Optiscan #BreastCancer #InVue #PrecisionSurgery #MedicalInnovation #Healthcare

Proud of our students - Thirrisha, Louis and Sarah - for working closely with the EMPD team at National Cancer Centre Singapore and publishing in Annals of Surgery Open! This systematic review and meta-analysis is (to our knowledge) the first attempt at collating available evidence on mapping biopsies in the surgical management of primary EMPD. We found that mapping biopsies were able to improve EMPD surgical excision outcomes, however, given the rarity of the disease and heterogeneity of mapping biopsy procedures, further confirmation with RCTs or a larger patient pool is necessary. https://lnkd.in/gqydbTci

🔬✨ Successfully Conducted: The First Clinical Surgical Oncology Forum of 2024 Unveils Innovations in Metastatic Disease Surgery On January 30th, the Clinical Surgical Oncology (CSO) forum brought together leading experts to explore "Innovations and Challenges in Surgery for Metastatic Disease." Led by Professor Tibor Kovacs, Professor Mark A Taylor and Professor Jian Zhou, the event showcased groundbreaking research and practical advancements in metastatic disease. Discussions centered on key topics such as liquid biopsy techniques, salvage surgery for liver cancer, and advancements in treating nasopharyngeal carcinoma. Under Professor Wen Yuan Chung's moderation, experts delved into patient-centered approaches and future directions in surgical oncology. The forum, marking the first of 2024, highlighted a commitment to advancing patient care and treatment outcomes. CSO Nova's establishment underscores the dedication to driving innovation in the field. Explore the special issue on "Surgery of Metastatic Disease" in Clinical Surgical Oncology: https://lnkd.in/gANF5QTV #ClinicalSurgicalOncology #SurgicalInnovations #MetastaticDisease #OncologyResearch #January30th 🚀🔬

Great collaboration with Reza Ghalehtaki, MD‼️ Just published a review on the role of #oxaliplatin in Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer - Treatment of locally advanced rectal cancer is challenging - Most approaches recommend neoadjuvant fluorouracil or capecitabine-based chemoradiotherapy followed by surgery - Intensification of concurrent chemotherapy by adding oxaliplatin to fluorouracil or capecitabine for better outcomes is unclear ‼️ 28 prospective phase II and III clinical trials were reviewed to answer this! 🤔 Some benefits in enhancing response to neoadjuvant chemoradiotherapy are evident however, without any translated improvements in long-term outcomes including overall and disease-free survival. Link to open access paper: https://lnkd.in/erzeH9qQ

March is Colorectal Cancer Awareness Month. The second leading cause of cancer death in the United States today is colorectal cancer, and approximately 150,000 people in the US will be diagnosed with the disease this year. The Vattikuti Foundation applauds robotic surgeons like Dr. Somashekhar SP, Dr. Kushal Agrawal, and the team from Aster International Institute of Oncology, Aster Hospital who have found ways to preserve nerve functionality for patients undergoing surgery for colorectal cancer. Surgical methods in the past commonly resulted in a high incidence of organ dysfunction, which severely compromised patient quality of life with complications such as low anterior rectal (LAR) syndrome and urogenital dysfunctions due to intraoperative inadvertent pelvic autonomic nerve damage after rectal cancer surgery. In their video submitted for KS International Innovation Awards 2023, the team from Aster Hospital discusses the current understanding of anatomy, key zones at risk of nerve injury and our experience with robotic platform in rectal surgery. Open call to innovative colorectal robotic surgeons: now's the time to prepare a video with your successful and innovative ways of using technology to help patients beat colorectal surgery. Your 8-minute electronic submission can be entered in the KS International Innovation Awards 2024 competition beginning April 15, 2024. Here is the link to the surgical video: https://lnkd.in/damNmg9Q Dr Kushal Agrawal Aster DM Healthcare ASTER MEDCITY Dr. Somashekhar S P Raj Vattikuti Mahendra Bhandari #colorectalcancer #colorectalcancerawareness #colorectal #roboticsurgeon #roboticsurgery #Surgery #surgeons #robotics #roboticschallenge #roboticsinnovation #KSAwards2024 #vattikutifoundation

Our peer-reviewed publication on the novel use of wide-field OCT and AI as a one-two combo punch to tackle breast cancer surgical oncology margins is out! You can read the details in the paper but the key statistics is 97% pathology positive margin identification while achieving 93% sensitivity and 98% specificity. Compare this number to the published results revealing 21.1% and 14.9% reoperation rates among commercially insured patients and the Medicare cohort (bit.ly/3wwMkp1). Many thanks to my co-authors Yanir Levy, David Rempel, Mark Nguyen, Ali Yassine, Maggie Sanati-Burns, Dr Payal Salgia, Bryant Lim, Sarah Butler, PhD, and Andrew Berkeley. Perimeter Medical Imaging AI, #AI, #OCT #breastcancer #margin #oncology #surgical